Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD

NCT01835067 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

55

Enrollment

OTHER

Sponsor class

Conditions

Exudative Macular Degeneration
Retinal Hemorrhage

Interventions

DRUG: Ranibizumab
DRUG: C3F8 Gas
DRUG: tPA

Sponsor

King's College Hospital NHS Trust